Laura A Dawson1, Kathryn A Winter2, Alan W Katz3, Michael C Schell3, James Brierley4, Yuhchyau Chen3, Neil Kopek5, Christopher H Crane6, Christopher G Willett7. 1. Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. Electronic address: Laura.Dawson@rmp.uhn.ca. 2. NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania. 3. Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York. 4. Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. 5. Department of Oncology, McGill University, Montreal, Quebec, Canada. 6. Memorial Sloan Kettering Cancer Center, Manhattan, New York. 7. Duke University Medical Center, Durham, North Carolina.
Abstract
PURPOSE: This study aimed to determine the feasibility and maximally tolerated dose of hypofractionated, conformal radiation therapy (RT) in patients with liver metastases. METHODS AND MATERIALS: Nonsurgical patients with ≤5 liver metastases (sum of maximal diameter of all lesions ≤8 cm) were included in the study. There were 4 dose levels: 35 Gy, 40 Gy (starting level), 45 Gy, and 50 Gy, in 10 fractions. The clinical target volume included metastases identified on contrast computed tomography or magnetic resonance imaging with a 5-mm margin within the liver. The planning target volume margin ranged from 4 to 30 mm, depending on breathing motion. Dose-limiting toxicities were defined as RT-related grade ≥4 hepatic or gastrointestinal toxicities or thrombocytopenia occurring within 90 days of the start of RT. RESULTS: A total of 26 patients with metastases from colorectal (8 patients), breast (7 patients) and other malignancies (11 patients) were enrolled between November 2005 and December 2010. Twenty-three patients were evaluable (8, 7, and 8 on the 40, 45, and 50 Gy dose levels, respectively). Two patients assigned to 50 Gy received 35 Gy owing to normal tissue limits, so 2 additional patients were treated to 50 Gy. There were no dose-limiting toxicities on any of the dose levels. On the 45 Gy dose level, 1 patient developed reversible grade 3 enteritis (37 days from RT start) and diarrhea (22 days); another patient developed grade 3 lymphopenia (23 days). At the 50 Gy dose level, 1 patient had grade 3 hyperglycemia (74 days), and another patient developed grade 3 lymphopenia (13 days), colonic hemorrhage (325 days), and colonic gastrointestinal obstruction (325 days). With a potential median follow-up of 66.1 months (range, 34.6-89.0 months), no other late toxicities were observed. CONCLUSIONS: Treatment of liver metastases with 50 Gy in 10 fractions was feasible and safe in a multi-institutional setting.
PURPOSE: This study aimed to determine the feasibility and maximally tolerated dose of hypofractionated, conformal radiation therapy (RT) in patients with liver metastases. METHODS AND MATERIALS: Nonsurgical patients with ≤5 liver metastases (sum of maximal diameter of all lesions ≤8 cm) were included in the study. There were 4 dose levels: 35 Gy, 40 Gy (starting level), 45 Gy, and 50 Gy, in 10 fractions. The clinical target volume included metastases identified on contrast computed tomography or magnetic resonance imaging with a 5-mm margin within the liver. The planning target volume margin ranged from 4 to 30 mm, depending on breathing motion. Dose-limiting toxicities were defined as RT-related grade ≥4 hepatic or gastrointestinal toxicities or thrombocytopenia occurring within 90 days of the start of RT. RESULTS: A total of 26 patients with metastases from colorectal (8 patients), breast (7 patients) and other malignancies (11 patients) were enrolled between November 2005 and December 2010. Twenty-three patients were evaluable (8, 7, and 8 on the 40, 45, and 50 Gy dose levels, respectively). Two patients assigned to 50 Gy received 35 Gy owing to normal tissue limits, so 2 additional patients were treated to 50 Gy. There were no dose-limiting toxicities on any of the dose levels. On the 45 Gy dose level, 1 patient developed reversible grade 3 enteritis (37 days from RT start) and diarrhea (22 days); another patient developed grade 3 lymphopenia (23 days). At the 50 Gy dose level, 1 patient had grade 3 hyperglycemia (74 days), and another patient developed grade 3 lymphopenia (13 days), colonic hemorrhage (325 days), and colonic gastrointestinal obstruction (325 days). With a potential median follow-up of 66.1 months (range, 34.6-89.0 months), no other late toxicities were observed. CONCLUSIONS: Treatment of liver metastases with 50 Gy in 10 fractions was feasible and safe in a multi-institutional setting.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Simon S Lo; Achilles J Fakiris; Bin S Teh; Higinia R Cardenes; Mark A Henderson; Jeffrey A Forquer; Lech Papiez; Ronald C McGarry; Jian Z Wang; Kaile Li; Nina A Mayr; Robert D Timmerman Journal: Expert Rev Anticancer Ther Date: 2009-05 Impact factor: 4.512
Authors: Scott Kopetz; George J Chang; Michael J Overman; Cathy Eng; Daniel J Sargent; David W Larson; Axel Grothey; Jean-Nicolas Vauthey; David M Nagorney; Robert R McWilliams Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: Alan W Katz; Madeleine Carey-Sampson; Ann G Muhs; Michael T Milano; Michael C Schell; Paul Okunieff Journal: Int J Radiat Oncol Biol Phys Date: 2006-12-29 Impact factor: 7.038
Authors: Edgar Ben-Josef; Daniel Normolle; William D Ensminger; Suzette Walker; Daniel Tatro; Randall K Ten Haken; James Knol; Laura A Dawson; Charlie Pan; Theodore S Lawrence Journal: J Clin Oncol Date: 2005-12-01 Impact factor: 44.544
Authors: A E M van der Pool; A Méndez Romero; W Wunderink; B J Heijmen; P C Levendag; C Verhoef; J N M Ijzermans Journal: Br J Surg Date: 2010-03 Impact factor: 6.939
Authors: Youjin Lee; Sogyong L Auh; Yugang Wang; Byron Burnette; Yang Wang; Yuru Meng; Michael Beckett; Rohit Sharma; Robert Chin; Tony Tu; Ralph R Weichselbaum; Yang-Xin Fu Journal: Blood Date: 2009-04-06 Impact factor: 22.113
Authors: Alice C Wei; Paul D Greig; David Grant; Bryce Taylor; Bernard Langer; Steven Gallinger Journal: Ann Surg Oncol Date: 2006-03-10 Impact factor: 5.344
Authors: Mark T Lee; John J Kim; Robert Dinniwell; James Brierley; Gina Lockwood; Rebecca Wong; Bernard Cummings; Jolie Ringash; Regina V Tse; Jennifer J Knox; Laura A Dawson Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: Kyle E Rusthoven; Brian D Kavanagh; Higinia Cardenes; Volker W Stieber; Stuart H Burri; Steven J Feigenberg; Mark A Chidel; Thomas J Pugh; Wilbur Franklin; Madeleine Kane; Laurie E Gaspar; Tracey E Schefter Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544